Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability

W. Jiang, H. Huang, L. Ding, P. Zhu, H. Saiyin, G. Ji, J. Zuo, D. Han, Y. Pan, D. Ding, X. Ma, Y. Zhang, J. Wu, Q. Yi, Jun Liu, H. Huang, Y. Dang, L. Yu

Research output: Contribution to journalArticle

Abstract

Activation of cyclin E1, a key regulator of the G1/S cell-cycle transition, has been implicated in many cancers including hepatocellular carcinoma (HCC). Although much is known about the regulation of cyclin E1 expression and stability, its post-transcriptional regulation mechanism remains incompletely understood. Here, we report that nuclear factor 90 (NF90), a double-stranded RNA (dsRNA) binding protein, regulates cyclin E1 in HCC. We demonstrate that NF90 is upregulated in HCC specimens and that suppression of NF90 decreases HCC cell growth and delays G1/S transition. We identified cyclin E1 as a new target of NF90 and found a significant correlation between NF90 and cyclin E1 expression in HCC. The mRNA and protein levels of cyclin E1 were downregulated upon NF90 knockdown. Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA, which was rescued by ectopic expression of NF90. Furthermore, NF90 bound to the 3' untranslated regions (3'UTRs) of cyclin E1 mRNA in vitro and in vivo. Knockdown of NF90 also inhibited tumor growth of HCC cell lines in mouse xenograft model. Moreover, we showed that inhibition of NF90 sensitized HCC cells to the cyclin-dependent kinase 2 (CDK2) inhibitor, roscovitine. Taken together, downregulation of NF90 in HCC cell lines can delay cell-cycle progression, inhibit cell proliferation, and reduce tumorigenic capacity in vivo. These results suggest that NF90 has an important role in HCC pathogenesis and that it can serve as a novel therapeutic target for HCC.

Original languageEnglish (US)
Pages (from-to)4460-4470
Number of pages11
JournalOncogene
Volume34
Issue number34
DOIs
StatePublished - Aug 20 2015

Fingerprint

Nuclear Factor 90 Proteins
Cyclins
RNA Stability
Hepatocellular Carcinoma
Cell Cycle
Messenger RNA
Down-Regulation
Cyclin-Dependent Kinase 2
Cell Line

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Jiang, W., Huang, H., Ding, L., Zhu, P., Saiyin, H., Ji, G., ... Yu, L. (2015). Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene, 34(34), 4460-4470. https://doi.org/10.1038/onc.2014.373

Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. / Jiang, W.; Huang, H.; Ding, L.; Zhu, P.; Saiyin, H.; Ji, G.; Zuo, J.; Han, D.; Pan, Y.; Ding, D.; Ma, X.; Zhang, Y.; Wu, J.; Yi, Q.; Liu, Jun; Huang, H.; Dang, Y.; Yu, L.

In: Oncogene, Vol. 34, No. 34, 20.08.2015, p. 4460-4470.

Research output: Contribution to journalArticle

Jiang, W, Huang, H, Ding, L, Zhu, P, Saiyin, H, Ji, G, Zuo, J, Han, D, Pan, Y, Ding, D, Ma, X, Zhang, Y, Wu, J, Yi, Q, Liu, J, Huang, H, Dang, Y & Yu, L 2015, 'Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability', Oncogene, vol. 34, no. 34, pp. 4460-4470. https://doi.org/10.1038/onc.2014.373
Jiang, W. ; Huang, H. ; Ding, L. ; Zhu, P. ; Saiyin, H. ; Ji, G. ; Zuo, J. ; Han, D. ; Pan, Y. ; Ding, D. ; Ma, X. ; Zhang, Y. ; Wu, J. ; Yi, Q. ; Liu, Jun ; Huang, H. ; Dang, Y. ; Yu, L. / Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. In: Oncogene. 2015 ; Vol. 34, No. 34. pp. 4460-4470.
@article{51f0acaee6af4cc49aa583be80e9682b,
title = "Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability",
abstract = "Activation of cyclin E1, a key regulator of the G1/S cell-cycle transition, has been implicated in many cancers including hepatocellular carcinoma (HCC). Although much is known about the regulation of cyclin E1 expression and stability, its post-transcriptional regulation mechanism remains incompletely understood. Here, we report that nuclear factor 90 (NF90), a double-stranded RNA (dsRNA) binding protein, regulates cyclin E1 in HCC. We demonstrate that NF90 is upregulated in HCC specimens and that suppression of NF90 decreases HCC cell growth and delays G1/S transition. We identified cyclin E1 as a new target of NF90 and found a significant correlation between NF90 and cyclin E1 expression in HCC. The mRNA and protein levels of cyclin E1 were downregulated upon NF90 knockdown. Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA, which was rescued by ectopic expression of NF90. Furthermore, NF90 bound to the 3' untranslated regions (3'UTRs) of cyclin E1 mRNA in vitro and in vivo. Knockdown of NF90 also inhibited tumor growth of HCC cell lines in mouse xenograft model. Moreover, we showed that inhibition of NF90 sensitized HCC cells to the cyclin-dependent kinase 2 (CDK2) inhibitor, roscovitine. Taken together, downregulation of NF90 in HCC cell lines can delay cell-cycle progression, inhibit cell proliferation, and reduce tumorigenic capacity in vivo. These results suggest that NF90 has an important role in HCC pathogenesis and that it can serve as a novel therapeutic target for HCC.",
author = "W. Jiang and H. Huang and L. Ding and P. Zhu and H. Saiyin and G. Ji and J. Zuo and D. Han and Y. Pan and D. Ding and X. Ma and Y. Zhang and J. Wu and Q. Yi and Jun Liu and H. Huang and Y. Dang and L. Yu",
year = "2015",
month = "8",
day = "20",
doi = "10.1038/onc.2014.373",
language = "English (US)",
volume = "34",
pages = "4460--4470",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "34",

}

TY - JOUR

T1 - Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability

AU - Jiang, W.

AU - Huang, H.

AU - Ding, L.

AU - Zhu, P.

AU - Saiyin, H.

AU - Ji, G.

AU - Zuo, J.

AU - Han, D.

AU - Pan, Y.

AU - Ding, D.

AU - Ma, X.

AU - Zhang, Y.

AU - Wu, J.

AU - Yi, Q.

AU - Liu, Jun

AU - Huang, H.

AU - Dang, Y.

AU - Yu, L.

PY - 2015/8/20

Y1 - 2015/8/20

N2 - Activation of cyclin E1, a key regulator of the G1/S cell-cycle transition, has been implicated in many cancers including hepatocellular carcinoma (HCC). Although much is known about the regulation of cyclin E1 expression and stability, its post-transcriptional regulation mechanism remains incompletely understood. Here, we report that nuclear factor 90 (NF90), a double-stranded RNA (dsRNA) binding protein, regulates cyclin E1 in HCC. We demonstrate that NF90 is upregulated in HCC specimens and that suppression of NF90 decreases HCC cell growth and delays G1/S transition. We identified cyclin E1 as a new target of NF90 and found a significant correlation between NF90 and cyclin E1 expression in HCC. The mRNA and protein levels of cyclin E1 were downregulated upon NF90 knockdown. Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA, which was rescued by ectopic expression of NF90. Furthermore, NF90 bound to the 3' untranslated regions (3'UTRs) of cyclin E1 mRNA in vitro and in vivo. Knockdown of NF90 also inhibited tumor growth of HCC cell lines in mouse xenograft model. Moreover, we showed that inhibition of NF90 sensitized HCC cells to the cyclin-dependent kinase 2 (CDK2) inhibitor, roscovitine. Taken together, downregulation of NF90 in HCC cell lines can delay cell-cycle progression, inhibit cell proliferation, and reduce tumorigenic capacity in vivo. These results suggest that NF90 has an important role in HCC pathogenesis and that it can serve as a novel therapeutic target for HCC.

AB - Activation of cyclin E1, a key regulator of the G1/S cell-cycle transition, has been implicated in many cancers including hepatocellular carcinoma (HCC). Although much is known about the regulation of cyclin E1 expression and stability, its post-transcriptional regulation mechanism remains incompletely understood. Here, we report that nuclear factor 90 (NF90), a double-stranded RNA (dsRNA) binding protein, regulates cyclin E1 in HCC. We demonstrate that NF90 is upregulated in HCC specimens and that suppression of NF90 decreases HCC cell growth and delays G1/S transition. We identified cyclin E1 as a new target of NF90 and found a significant correlation between NF90 and cyclin E1 expression in HCC. The mRNA and protein levels of cyclin E1 were downregulated upon NF90 knockdown. Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA, which was rescued by ectopic expression of NF90. Furthermore, NF90 bound to the 3' untranslated regions (3'UTRs) of cyclin E1 mRNA in vitro and in vivo. Knockdown of NF90 also inhibited tumor growth of HCC cell lines in mouse xenograft model. Moreover, we showed that inhibition of NF90 sensitized HCC cells to the cyclin-dependent kinase 2 (CDK2) inhibitor, roscovitine. Taken together, downregulation of NF90 in HCC cell lines can delay cell-cycle progression, inhibit cell proliferation, and reduce tumorigenic capacity in vivo. These results suggest that NF90 has an important role in HCC pathogenesis and that it can serve as a novel therapeutic target for HCC.

UR - http://www.scopus.com/inward/record.url?scp=84939774818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939774818&partnerID=8YFLogxK

U2 - 10.1038/onc.2014.373

DO - 10.1038/onc.2014.373

M3 - Article

C2 - 25399696

AN - SCOPUS:84939774818

VL - 34

SP - 4460

EP - 4470

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 34

ER -